arrow
C

Cezary Szczylik

military medical institute
H指数:65
被引数:3.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 男性患者的最终总生存结果:来自随机、安慰剂对照、III期 TALAPRO-2 试验的数据

2025-07-160
PRE
Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study

talazoparib和enzalutamide在先前接受过雄激素受体通路抑制剂(ARPI)或多西他赛的mCRPC患者中的疗效:来自TALAPRO-2研究两个队列的事后分析

2024-09-011
PRE
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

TALAPRO-2研究结果的简明语言摘要: 塔拉唑帕利加恩扎鲁他胺与安慰剂加恩扎鲁他胺治疗晚期前列腺癌的比较

2024-07-121
OAAI
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Talazoparib联合恩扎鲁他胺治疗一线转移性去势抵抗性前列腺癌 (TALAPRO-2): 一项随机、安慰剂对照、3期临床试验

LANCET
IF88.5
2023-07-01181
PRE
Targeted sequencing of cancer-related genes reveals a recurrent TOP2A variant which affects DNA binding and coincides with global transcriptional changes in glioblastoma
2023-06-205
PRE
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

帕博利珠单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌的比较

2019-03-212.4K
OAAI